Is asciminib an effective tyrosine kinase inhibitor for chronic myeloid leukemia patients with tyrosine kinase inhibitor resistance?
Asciminib represents a significant advancement in the treatment of chronic myeloid leukemia, establishing a novel therapeutic paradigm by specifically targeting the ABL1 myristoyl pocket, a mechanism distinct from that of conventional adenosine triphosphate-competitive inhibitors. Such a selective i...
Kaydedildi:
| Asıl Yazarlar: | , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Elsevier
2026-04-01
|
| Seri Bilgileri: | Hematology, Transfusion and Cell Therapy |
| Konular: | |
| Online Erişim: | http://www.sciencedirect.com/science/article/pii/S2531137926000040 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|